Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN12 | Q05209 | 1/20 | 0.45 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HTT | P42858 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764621 | 0.95 | PTPN12 (0.40) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6767728 | 0.92 | PTPN12 (0.44) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL6214333 | 0.90 | HTT (0.53) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6767355 | 0.87 | PDE5A (0.36) | PTPN12PTPN22ALDH1A1LMNATP53 | |
| SCHEMBL6212763 | 0.87 | GAA (0.49) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6635079 | 0.86 | HSD17B10 (0.38) | PTPN12PTPN22SMN1; SMN2ALDH1A1PDE5A | |
| SCHEMBL7674732 | 0.86 | GAA (0.49) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| Bicarbonate SCHEMBL6216576 | 0.85 | HTT (0.47) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6764817 | 0.83 | PTPN12 (0.48) | PTPN12PTPN22GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL6218376 | 0.83 | PDE5A (0.41) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| US-20030022906-A1 | Use of pde v inhibitors | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | PTPN12 1903/4885PTPN22 1940/4885GAA 1376/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | PTPN12 2787/4885PTPN22 2711/4885GAA 2391/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | PTPN12 3109/4885PTPN22 3400/4885GAA 3683/4885 |
| US-20030022906-A1 | Use of pde v inhibitors | PDE3A, PDE5A, PDE2A | PTPN12 955/4885PTPN22 1462/4885GAA 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.